BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33010027)

  • 21. Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Results from the SEER Program, 1978-1998.
    Mink PJ; Sherman ME; Devesa SS
    Cancer; 2002 Dec; 95(11):2380-9. PubMed ID: 12436446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ovarian epithelial tumors of borderline malignancy in Japan.
    Nakashima N; Nagasaka T; Oiwa N; Nara Y; Fukata S; Fukatsu T; Takeuchi J
    Gynecol Oncol; 1990 Jul; 38(1):90-8. PubMed ID: 2162318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hormone therapy and different ovarian cancers: a national cohort study.
    Mørch LS; Løkkegaard E; Andreasen AH; Kjaer SK; Lidegaard O
    Am J Epidemiol; 2012 Jun; 175(12):1234-42. PubMed ID: 22517811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk for borderline ovarian tumours after exposure to fertility drugs: results of a population-based cohort study.
    Bjørnholt SM; Kjaer SK; Nielsen TS; Jensen A
    Hum Reprod; 2015 Jan; 30(1):222-31. PubMed ID: 25376453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Base of tongue/tonsillar and laryngeal cancer in Denmark 1994-2018: Temporal trends in incidence according to education and age.
    de la Cour CD; Munk C; Aalborg GL; Kjaer SK
    Oral Oncol; 2022 May; 128():105832. PubMed ID: 35413640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Borderline ovarian tumors in Finland: epidemiology and familial occurrence.
    Auranen A; Grénman S; Mäkinen J; Pukkala E; Sankila R; Salmi T
    Am J Epidemiol; 1996 Sep; 144(6):548-53. PubMed ID: 8797514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study.
    Riman T; Dickman PW; Nilsson S; Correia N; Nordlinder H; Magnusson CM; Persson IR
    Gynecol Oncol; 2001 Dec; 83(3):575-85. PubMed ID: 11733975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Second neoplasms after invasive and borderline ovarian cancer.
    Levi F; Randimbison L; Blanc-Moya R; La Vecchia C
    Eur J Cancer Prev; 2009 Jun; 18(3):216-9. PubMed ID: 19491608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The association of reproductive factors with risk of non-epithelial ovarian cancer and comparison with serous ovarian cancer.
    Hemmingsen CH; Kjaer SK; Bennetsen AKK; Dehlendorff C; Baandrup L
    Gynecol Oncol; 2021 Aug; 162(2):469-474. PubMed ID: 34016454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A nationwide study of serous "borderline" ovarian tumors in Denmark 1978-2002: centralized pathology review and overall survival compared with the general population.
    Hannibal CG; Vang R; Junge J; Frederiksen K; Kjaerbye-Thygesen A; Andersen KK; Tabor A; Kurman RJ; Kjaer SK
    Gynecol Oncol; 2014 Aug; 134(2):267-73. PubMed ID: 24924123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Ovarian tumors of low malignant potential (borderline ovarian tumors)].
    Luchian AM; Pricop M
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(2):438-45. PubMed ID: 21870737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risks of non-ovarian cancers in women with borderline ovarian tumor: a national cohort study in Sweden.
    Dobilas A; Jansåker F; Li X; Sundquist K; Borgfeldt C
    BMC Cancer; 2023 Oct; 23(1):951. PubMed ID: 37807065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ovarian cancer incidence in the United States, 1992-1999.
    Quirk JT; Natarajan N
    Gynecol Oncol; 2005 May; 97(2):519-23. PubMed ID: 15863154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-malignant potential epithelial tumors of the ovary: a clinicopathological study.
    Hassan E; Koumantaki Y; Stefanaki K; Matalliotakis I; Koumantakis E
    Eur J Gynaecol Oncol; 1998; 19(2):170-2. PubMed ID: 9611060
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic imbalances in ovarian borderline serous and mucinous tumors.
    Hu J; Khanna V; Jones MM; Surti U
    Cancer Genet Cytogenet; 2002 Nov; 139(1):18-23. PubMed ID: 12547152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trends in the incidence of ovarian cancer and borderline tumours in Norway, 1954-1993.
    Bjørge T; Engeland A; Hansen S; Tropé CG
    Int J Cancer; 1997 May; 71(5):780-6. PubMed ID: 9180146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum?
    Jordan SJ; Green AC; Whiteman DC; Webb PM;
    Gynecol Oncol; 2007 Nov; 107(2):223-30. PubMed ID: 17662378
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drugs with potential chemopreventive properties in relation to epithelial ovarian cancer--a nationwide case-control study.
    Baandrup L
    Dan Med J; 2015 Jul; 62(7):. PubMed ID: 26183052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathologic features of ovarian neoplasms with emphasis on borderline ovarian tumors: an institutional perspective.
    Hashmi AA; Hussain ZF; Bhagwani AR; Edhi MM; Faridi N; Hussain SD; Khan M
    BMC Res Notes; 2016 Apr; 9():205. PubMed ID: 27052022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.